ISB News

ISB’s Robert Moritz Lab Receives NIGMS Grant for Trans Proteomic Pipeline

The National Institute Of General Medical Sciences of the NIH has awarded Principal Investigator(s): Eric Deutsch, PhD, and Robert L. Moritz, PhD, a continuing R01 grant GM087221 for the ongoing development of the Trans-Proteomic Pipeline. The award titled “Development of Trans Proteomic Pipeline, an Analysis Suite for Mass Spectrometry” will continue the work of the ISB flagship proteomics analysis suite of open-source programs that has been downloaded thousands of times by researchers worldwide. The TPP team will continue on its effort of building new tools and teaching researchers (see previous post about ISB’s TPP course) from across the globe how to access new statistical validation and cloud-enabled components of the TPP. The grant will provide ISB with direct costs of $287,000 each year for the next 4 years for Deutsch, Luis Mendoza, David Shteynberg and Zhi Sun of the Moritz group to continue this work.

Recent Articles

  • 2024 Year in Review

    Reflecting on the past year, ISB has a lot to celebrate: groundbreaking research published in leading scientific journals, well-earned promotions, widespread media coverage, and more. Enjoy our year-in-review roundup highlighting some of the important, interesting, and impactful highlights of 2024.

  • My Digital Gut

    ISB Named Winner of 2024-2025 Amazon Web Services IMAGINE Grant for Nonprofits

    ISB has been selected as a winner of the 2024 Amazon Web Services (AWS) IMAGINE Grant. The grant will support ISB’s continued development of My Digital Gut, an online decision-support platform that will help make microbiome-informed nutrition and healthcare personalized, predictive, and preventive. 

  • ISB-Developed MetaboCore Offers Precision Cancer Care Faster Than Ever 

    ISB Associate Professor Dr. Wei Wei and his colleagues have developed a promising new companion diagnostic tool called MetaboCore to help physicians quickly select the most effective systemic therapy for each cancer patient.